What is claimed is:

1. A method of treating or preventing a disease mediated by monoamine oxidase B inhibitors comprising administering to a patient in need of such treatment a therapeutically effective amount of at least one compound of the formula



I

wherein

X is –N= or –CH=;

R^1 is –CO-NR^5R^6;

-CHR^7-$(CH_2)_n$-CO-NR^5R^6;

-$(CH_2)_n$-NR^5R^6;

-$(CH_2)_n$-$COOR^8$;

-$(CH_2)_n$-CN;

-CHR^7-$(CH_2)_n$-CF_3;

-$(CH_2)_n$-NH-COR^9;

-$(CH_2)_n$-NH-$COOR^8$;

a heterocyclic ring-containing group selected from -$(CH_2)_n$-piperidinyl, -$(CH_2)_n$-morpholinyl, -$(CH_2)_n$-tetrahydrofuranyl; -$(CH_2)_n$-thiophenyl or -$(CH_2)_n$-isoxazolyl, wherein the heterocyclic ring may be substituted by C_1-C_6-alkyl;

a phenyl;

-$(CH_2)_n$-phenyl, wherein the phenyl ring may be substituted by halogen or halogen-(C_1-C_6)-alkyl;

-$(CH_2)_p$-OR^8;

-$(CH_2)_p$-SR^8;

$-(CH_2)_p-SO-R^9$; or

$-(CH_2)_n-CS-NR^5R^6$;

R^2 is hydrogen;

C_1-C_6-alkyl;

$-(CH_2)_p-OR^{10}$;

$-(CH_2)_p-SR^{10}$; or benzyl;

R^3 is hydrogen or C_1-C_6-alkyl;

R^4 is halogen, halogen-(C_1-C_6)-alkyl, cyano, C_1-C_6-alkoxy or halogen-(C_1-C_6)-alkoxy;

R^5 and R^6 are independently from each other hydrogen or C_1-C_6-alkyl;

R^7 is hydrogen, hydroxy or C_1-C_6-alkoxy;

R^8 is hydrogen or C_1-C_6-alkyl;

R^9 is C_1-C_6-alkyl;

R^{10} is hydrogen or C_1-C_6-alkyl;

m is 1, 2 or 3;

n is 0, 1 or 2; and

p is 1 or 2;

or a pharmaceutically acceptable salt thereof.

2. The method according to claim 1 wherein the disease comprises Alheimer's disease and senile dementia.

3. A process for the manufacture of a compound of formula I



I

wherein

X is –N= or –CH=;

R^1 is $-CO-NR^5R^6$;

$-CHR^7-(CH_2)_n-CO-NR^5R^6$;

$-(CH_2)_n-NR^5R^6$;

$-(CH_2)_n-COOR^8$;

$-(CH_2)_n-CN$;

$-CHR^7-(CH_2)_n-CF_3$;

$-(CH_2)_n-NH-COR^9$;

$-(CH_2)_n-NH-COOR^8$;

a heterocyclic ring-containing group selected from $-(CH_2)_n$-piperidinyl, $-(CH_2)_n$-morpholinyl, $-(CH_2)_n$-tetrahydrofuranyl; $-(CH_2)_n$-thiophenyl or $-(CH_2)_n$-isoxazolyl, wherein the heterocyclic ring may be substituted by C_1-C_6-alkyl;

a phenyl;

$-(CH_2)_n$-phenyl, wherein the phenyl ring may be substituted by halogen or halogen-(C_1-C_6)-alkyl;

$-(CH_2)_p-OR^8$;

$-(CH_2)_p-SR^8$;

$-(CH_2)_p-SO-R^9$; or

$-(CH_2)_n-CS-NR^5R^6$;

R^2 is hydrogen;

C_1-C_6-alkyl;

$-(CH_2)_p-OR^{10}$;

$-(CH_2)_p-SR^{10}$; or benzyl;

R^3 is hydrogen or C_1-C_6-alkyl;

R^4 is halogen, halogen-(C_1-C_6)-alkyl, cyano, C_1-C_6-alkoxy or halogen-(C_1-C_6)-alkoxy;

R^5 and R^6 are independently from each other hydrogen or C_1-C_6-alkyl;

R^7 is hydrogen, hydroxy or C_1-C_6-alkoxy;

R^8 is hydrogen or C_1-C_6-alkyl;

R^9 is C_1-C_6-alkyl;

R^{10} is hydrogen or C_1-C_6-alkyl;

m is 1, 2 or 3;

n is 0, 1 or 2; and

p is 1 or 2;

which process comprises

a) reacting a compound of formula



II

with a compound of formula



III

4. A process for the manufacture of a compound of formula I



I

wherein

X is –N= or –CH=;

R^1 is $-CO-NR^5R^6$;

$-CHR^7-(CH_2)_n-CO-NR^5R^6$;

$-(CH_2)_n-NR^5R^6$;

$-(CH_2)_n-COOR^8$;

$-(CH_2)_n-CN$;

$-CHR^7-(CH_2)_n-CF_3$;

$-(CH_2)_n-NH-COR^9$;

$-(CH_2)_n-NH-COOR^8$;

a heterocyclic ring-containing group selected from-$(CH_2)_n$-piperidinyl, -$(CH_2)_n$-morpholinyl, -$(CH_2)_n$-tetrahydrofuranyl; -$(CH_2)_n$-thiophenyl or -$(CH_2)_n$-isoxazolyl, wherein the heterocyclic ring may be substituted by C_1-C_6-alkyl;

a phenyl;

-$(CH_2)_n$-phenyl, wherein the phenyl ring may be substituted by halogen or halogen-(C_1-C_6)-alkyl;

$-(CH_2)_P-OR^8$;

$-(CH_2)_p-SR^8$;

$-(CH_2)_p-SO-R^9$; or

$-(CH_2)_n-CS-NR^5R^6$;

R^2 is hydrogen;

C_1-C_6-alkyl;

$-(CH_2)_p-OR^{10}$;

$-(CH_2)_p-SR^{10}$; or benzyl;

R^3 is hydrogen or C_1-C_6-alkyl;

R^4 is halogen, halogen-(C_1-C_6)-alkyl, cyano, C_1-C_6-alkoxy or halogen-(C_1-C_6)-alkoxy;

R^5 and R^6 are independently from each other hydrogen or C_1-C_6-alkyl;

R^7 is hydrogen, hydroxy or C_1-C_6-alkoxy;

R^8 is hydrogen or C_1-C_6-alkyl;

R^9 is C_1-C_6-alkyl;

R^{10} is hydrogen or C_1-C_6-alkyl;

m is 1, 2 or 3;

n is 0, 1 or 2; and

p is 1 or 2;

which process comprises reacting a compound of formula



IV

with a compound of formula



V

5. The process according to claim 3 further comprising converting the compound into a pharmaceutically acceptable salt.

6. The process according to claim 4 further comprising converting the compound into a pharmaceutically acceptable salt.